Heart Failure

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone reduced risk for CV death and worsening HF by 16% compared with placebo, researchers reported at the European Society of Cardiology Congress.

Transcatheter mitral valve repair in addition to medical therapy led to a lower rate of CV events and hospitalizations and better health status compared with medical therapy alone for patients with HF and moderate to severe mitral regurgitation.

Adults with prediabetes and overweight or obesity who take the GIP/GLP-1 dual agonist tirzepatide once weekly may be 94% less likely to develop type 2 diabetes, according to results from the SURMOUNT-1 study.

A genetics-based platelet reactivity score can help identify people with a hyperreactive platelet phenotype who may have increased risk for a cardiovascular event, according to research published in Nature Communications.

Adults with subclinical hypothyroidism may have a lower risk for major adverse cardiovascular events if they receive levothyroxine therapy compared with no treatment, according to a study published in Thyroid.

Patients with cancer who received immune checkpoint inhibitors rarely developed cardiovascular adverse events, according to results of a systematic review and meta-analysis.

A novel prognostic model identified risk factors including smoking, obesity, HbA1c and albuminuria as significant predictors of incident heart failure risk among Native American adults, researchers reported.

Twelve circulating proteins associated with obesity and heart failure may inform treatment for adults with both conditions, according to a study published in Obesity.

Benzodiazepines were associated with increased risk for CHD, HF and CV mortality among patients with insomnia, according to a study published in the European Journal of Preventive Cardiology.